Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
123.54
-1.53 (-1.22%)
At close: Jul 10, 2026, 4:00 PM EDT
124.37
+0.83 (0.67%)
Pre-market: Jul 13, 2026, 5:58 AM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $16.29B in the quarter ending March 31, 2026, with 4.87% growth. This brings the company's revenue in the last twelve months to $65.77B, up 2.89% year-over-year. In the year 2025, Merck & Co. had annual revenue of $65.01B with 1.31% growth.
Revenue (ttm)
$65.77B
Revenue Growth
+2.89%
P/S Ratio
4.64
Revenue / Employee
$876,907
Employees
75,000
Market Cap
305.12B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.01B | 843.00M | 1.31% |
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
MRK News
- 2 days ago - Merck confirms FDA approves Keytruda combos with Padcev - TheFly
- 2 days ago - FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC) - Business Wire
- 2 days ago - FDA approves Keytruda combos for certain muscle invasive bladder cancer cases - TheFly
- 4 days ago - Redwire appoints Paul Reichert, Niki Werkheiser as SpaceMD advisors - TheFly
- 4 days ago - Merck price target raised to $150 from $145 at Wells Fargo - TheFly
- 6 days ago - Merck price target raised to $150 from $135 at HSBC - TheFly
- 11 days ago - Merck terminates Phase 2 Alzheimer’s study - TheFly
- 11 days ago - Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - Business Wire